Managers / Q4 2023 · view latest →
Weaver C. Barksdale & Associates, Inc.
CIK 0001294588 · 40 BURTON HILLS BLVD., SUITE 230, NASHVILLE, TN, 37215 · 615-665-1085
Summary
Weaver C. Barksdale & Associates, Inc. reported $102M in U.S.-listed holdings across 62 positions for Q4 2023.
Its largest position, AVGO, represents 2.5% of the portfolio.
The book was largely unchanged from Q3 2023.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 90.9% · $93M
- REIT · 4.6% · $5M
- Other · 4.5% · $5M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| AVGOBROADCOM INC | TRIMMED | −1.2K | 2.3K | −$371,107 | $3M |
| MRKMERCK & CO INC | TRIMMED | −4.3K | 12.4K | −$363,603 | $1M |
| PFEPFIZER INC | TRIMMED | −11.9K | 34.9K | −$547,329 | $1M |
| BMYBRISTOL-MYERS SQUIBB CO | TRIMMED | −7.3K | 21.4K | −$566,984 | $1M |
| PSXPHILLIPS 66 | TRIMMED | −5.4K | 18.5K | −$404,411 | $2M |
| JNJJOHNSON & JOHNSON | TRIMMED | −2.3K | 8.3K | −$347,601 | $1M |
| GILDGILEAD SCIENCES INC | TRIMMED | −6.8K | 25.7K | −$352,230 | $2M |
| ITWILLINOIS TOOL WKS INC | TRIMMED | −2.2K | 8.3K | −$238,587 | $2M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2023
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $105M | 62 | May 14, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $95M | 62 | Feb 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $104M | 62 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $104M | 62 | Aug 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $104M | 62 | May 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $104M | 62 | Feb 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $111M | 62 | Nov 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $105M | 62 | Aug 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $109M | 62 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $102M | 62 | Feb 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $117M | 62 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $101M | 62 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $107M | 62 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $113M | 62 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $100M | 63 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $107M | 63 | Aug 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $112M | 61 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $110M | 59 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.